Search results
Results from the WOW.Com Content Network
The autism-spectrum quotient (AQ) is a questionnaire published in 2001 by Simon Baron-Cohen and his colleagues at the Autism Research Centre in Cambridge, UK.Consisting of fifty questions, it aims to investigate whether adults of average intelligence (defined as an IQ of 80 or higher by the questionnaire) have symptoms of autism spectrum conditions. [1]
The research: One recent study found that people who completed BrainHQ brain-training exercises for 10 weeks did better on balance and walking tests than people who did no training.
It takes a lot of brainpower to create BrainHQ’s brain training program.And much of that belongs to one man: Michael Merzenich, Ph.D., a professor emeritus at University of California San ...
Take the quiz. Are you 65 or older? Take this quiz below to see if your brain could use a tune-up. (Do you have a Medicare Advantage plan? You might get access to BrainHQ at no additional cost to you.
The Ritvo Autism & Asperger Diagnostic Scale (RAADS) is a psychological self-rating scale developed by Riva Ariella Ritvo (NPI UCLA and CSC Yale). An abridged and translated 14 question version was then developed at the Department of Clinical Neuroscience at the Karolinska Institute, to aid in the identification of patients who may have undiagnosed ASD.
Process for screening and diagnosing ASD; M-CHAT is Modified Checklist for Autism in Toddlers; (+) is positive test result; (−) is negative test result. There are several factors that make autism spectrum disorder difficult to diagnose. First off, there are no standardized imaging, molecular or genetic tests that can be used to diagnose ASD. [4]
While most brain games lack any proof of effectiveness, BrainHQ’s benefits have been shown in hundreds of clinical studies. Your brain health matters! BrainHQ rewires the brain so you can think ...
Posit Science Corporation is an American company providing brain training software and services. [1] [2]Originally known as Neuroscience Solutions Corporation, the company was founded in 2002 by neuroscientists Michael Merzenich and Henry Mahncke, who originally intended to help people with schizophrenia. [3]